The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.

Elliot MarseilleJames G KahnBerra Yazar-KlosinskiRick Doblin

Published in: PloS one (2020)

MAP provided to patients with severe or extreme, chronic PTSD appears to be cost-saving while delivering substantial clinical benefit. Third-party payers are likely to save money within three years by covering this form of therapy.

Keyphrases

posttraumatic stress disorder
social support
drug induced
climate change
early onset
stem cells
depressive symptoms